Nasus Pharma Ltd Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances
Nasus Pharma Ltd (NSRX) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances of $435.00 thousand for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-25.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues · last filed 2026-03-25
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 12 month |
|---|---|---|
| 2025-12-31 | $435.00K 20-F · filed 2026-03-25 | |
| 2025-06-30 | $435.00K 6-K · filed 2025-12-29 | |
| 2024-12-31 | $1.00M 20-F · filed 2026-03-25 | |
| 2024-06-30 | $950.00K 6-K · filed 2025-12-29 | |
| 2023-12-31 | $995.00K 20-F · filed 2026-03-25 |